This is Eli Lilly’s focus
In an interview with MedWatch, the head of Eli Lilly’s Scandinavian oncology department talks about the company’s M&A strategy, including which disease areas the US group will focus on.
BY STEFAN SINGH KAILAY
Eli Lilly has been an independent company since 1876, the US-based drug group has not been through any major mergers, and nor are they likely to go through any in the future.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Krogsgaard: Lilly could pave the way for Novo
For abonnenter
Eli Lilly presents new data on Victoza challenger
For abonnenter
